Ticagrelor Reduces Thromboinflammatory Markers in Patients With Pneumonia
Travis R Sexton, Guoying Zhang, Tracy E Macaulay, Leigh A Callahan, Richard Charnigo, Olga A Vsevolozhskaya, Zhenyu Li, Susan Smyth, Travis R Sexton, Guoying Zhang, Tracy E Macaulay, Leigh A Callahan, Richard Charnigo, Olga A Vsevolozhskaya, Zhenyu Li, Susan Smyth
Abstract
Despite treatment advances for sepsis and pneumonia, significant improvements in outcome have not been realized. Antiplatelet therapy may improve outcome in pneumonia and sepsis. In this study, the authors show that ticagrelor reduced leukocytes with attached platelets as well as the inflammatory biomarker interleukin (IL)-6. Pneumonia patients receiving ticagrelor required less supplemental oxygen and lung function tests trended toward improvement. Disruption of the P2Y12 receptor in a murine model protected against inflammatory response, lung permeability, and mortality. Results indicate a mechanistic link between platelets, leukocytes, and lung injury in settings of pneumonia and sepsis, and suggest possible therapeutic approaches to reduce complications.(Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor [XANTHIPPE]; NCT01883869).
Keywords: ADP, adenosine diphosphate; CAP, community-acquired pneumonia; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ELISA, enzyme-linked immunosorbent assay; FEV-1, forced expiratory volume in 1 s; HAP, hospital-acquired pneumonia; IL, interleukin; IQR, interquartile range; Kfc, capillary filtration coefficient; LPS, lipopolysaccharide; LTA, light transmission aggregometry; MPO, myeloperoxidase; MVV, maximum ventilation velocity; NE, neutrophil elastase; NET, neutrophil extracellular trap; OR, odds ratio; PRP, platelet-rich plasma; TNF, tumor necrosis factor; TRAP, thrombin receptor activating peptide; WT, wild-type; dsDNA, doubled-stranded DNA; inflammation; leukocytes; platelets; pneumonia; sepsis.
Figures
References
- Restrepo M.I., Faverio P., Anzueto A. Long-term prognosis in community-acquired pneumonia. Curr Opin Infect Dis. 2013;26:151–158.
- Cangemi R., Casciaro M., Rossi E. Platelet activation is associated with myocardial infarction in patients with pneumonia. J Am Coll Cardiol. 2014;64:1917–1925.
- Chen L.F., Chen H.P., Huang Y.S., Huang K.Y., Chou P., Lee C.C. Pneumococcal pneumonia and the risk of stroke: a population-based follow-up study. PLoS One. 2012;7:e51452.
- Chiang C.H., Huang C.C., Chan W.L. Association between Mycoplasma pneumonia and increased risk of ischemic stroke: a nationwide study. Stroke. 2011;42:2940–2943.
- Mandal P., Chalmers J.D., Choudhury G., Akram A.R., Hill A.T. Vascular complications are associated with poor outcome in community-acquired pneumonia. QJM. 2011;104:489–495.
- Ribeiro D.D., Lijfering W.M., Van Hylckama Vlieg A., Rosendaal F.R., Cannegieter S.C. Pneumonia and risk of venous thrombosis: results from the MEGA study. J Thromb Haemost. 2012;10:1179–1182.
- Ruane L., Buckley T., Hoo S.Y.S. Triggering of acute myocardial infarction by respiratory infection. Intern Med J. 2017;47:522–529.
- Smeeth L., Cook C., Thomas S., Hall A.J., Hubbard R., Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006;367:1075–1079.
- Smeeth L., Thomas S.L., Hall A.J., Hubbard R., Farrington P., Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611–2618.
- Caudrillier A., Kessenbrock K., Gilliss B.M. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest. 2012;122:2661–2671.
- Grommes J., Alard J.E., Drechsler M. Disruption of platelet-derived chemokine heteromers prevents neutrophil extravasation in acute lung injury. Am J Respir Crit Care Med. 2012;185:628–636.
- Weyrich A.S., Zimmerman G.A. Platelets in lung biology. Annu Rev Physiol. 2013;75:569–591.
- Gross A.K., Dunn S.P., Feola D.J. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis. 2013;35:147–154.
- Winning J., Reichel J., Eisenhut Y. Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets. 2009;20:50–57.
- Winning J., Neumann J., Kohl M. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med. 2010;38:32–37.
- Storey R.F., James S.K., Siegbahn A. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets. 2014;25:517–525.
- Andell P., James S.K., Cannon C.P. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial. J Am Heart Assoc. 2015;4:e002490.
- Rondina M.T., Carlisle M., Fraughton T. Platelet-monocyte aggregate formation and mortality risk in older patients with severe sepsis and septic shock. J Gerontol A Biol Sci Med Sci. 2015;70:225–231.
- Czaikoski P.G., Mota J.M., Nascimento D.C. Neutrophil extracellular traps induce organ damage during experimental and clinical sepsis. PLoS One. 2016;11:e0148142.
- Lowe K.L., Finney B.A., Deppermann C. Podoplanin and CLEC-2 drive cerebrovascular patterning and integrity during development. Blood. 2015;125:3769–3777.
- Sexton T.R., Wallace E.L., Macaulay T.E. The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome. J Thromb Thrombolysis. 2015;39:186–195.
- Sexton T.R., Wallace E.L., Chen A. Thromboinflammatory response and predictors of outcomes in patients undergoing transcatheter aortic valve replacement. J Thromb Thrombolysis. 2016;41:384–393.
- Miller M.R., Hankinson J., Brusasco V. Standardisation of spirometry. Eur Respir J. 2005;26:319–338.
- Foster C.J., Prosser D.M., Agans J.M. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest. 2001;107:1591–1598.
- Zarbock A., Ley K. The role of platelets in acute lung injury (ALI) Front Biosci (Landmark Ed) 2009;14:150–158.
- Cannon C.P., Harrington R.A., James S. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375:283–293.
- Seidel M., Winning J., Claus R.A., Bauer M., Losche W. Beneficial effect of clopidogrel in a mouse model of polymicrobial sepsis. J Thromb Haemost. 2009;7:1030–1032.
- Liverani E., Rico M.C., Tsygankov A.Y., Kilpatrick L.E., Kunapuli S.P. P2Y12 receptor modulates sepsis-induced inflammation. Arterioscler Thromb Vasc Biol. 2016;36:961–971.
- Winning J., Claus R.A., Pletz M.W., Bauer M., Losche W. Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model. Shock. 2011;36:317. author reply 318.
- Alexopoulos D., Galati A., Xanthopoulou I. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol. 2012;60:193–199.
- Li P., Yang Y., Chen T. Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. Sci Rep. 2015;5:13789.
- Cattaneo M., Schulz R., Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014;63:2503–2509.
- Tunjungputri R.N., Van Der Ven A.J., Schonsberg A. Reduced platelet hyperreactivity and platelet-monocyte aggregation in HIV-infected individuals receiving a raltegravir-based regimen. AIDS. 2014;28:2091–2096.
- Schoergenhofer C., Schwameis M., Hobl E.L. Potent irreversible P2Y12 inhibition does not reduce LPS-induced coagulation activation in a randomized, double-blind, placebo-controlled trial. Clin Sci (Lond) 2016;130:433–440.
- Akinosoglou K., Alexopoulos D. Use of antiplatelet agents in sepsis: a glimpse into the future. Thromb Res. 2014;133:131–138.
- Kuebler W.M. Selectins revisited: the emerging role of platelets in inflammatory lung disease. J Clin Invest. 2006;116:3106–3108.
Source: PubMed